Literature DB >> 6628452

Gaucher disease--Norrbottnian type. Neurodevelopmental, neurological, and neurophysiological aspects.

S Blom, A Erikson.   

Abstract

Neurodevelopmental, neurological and neurophysiological aspects of the Norrbottnian type of Gaucher disease (type III) were studied in 22 patients. The findings were related to clinical stages and to whether or not the patients had been splenectomized. Neurological abnormalities were mainly found in splenectomized patients who had passed the first decade of life. The EEG findings were not diagnostic for the disease, but changes were more common in the advanced stages and among splenectomized patients. The patterns of development of neurological and neurophysiological features indicate that CNS deposition of glucosylceramide increases after splenectomy, and favor a restrictive attitude towards surgery.

Entities:  

Mesh:

Year:  1983        PMID: 6628452     DOI: 10.1007/bf00442672

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Ectopic dendritic growth in mature pyramidal neurones in human ganglioside storage disease.

Authors:  D P Purpura
Journal:  Nature       Date:  1978-11-30       Impact factor: 49.962

2.  Neurological signs in a juvenile form of Gaucher's disease.

Authors:  K M HERRLIN; P O HILLBORG
Journal:  Acta Paediatr       Date:  1962-03       Impact factor: 2.299

3.  A case of juvenile Gaucher's disease with intraneuronal lipid storage.

Authors:  A F MALONEY; J N CUMINGS
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-08       Impact factor: 10.154

4.  The motor age test: measurement of motor handicaps in children with neuromuscular disorders such as cerebral palsy.

Authors:  M K JOHNSON; F N ZUCK; K WINGATE
Journal:  J Bone Joint Surg Am       Date:  1951-07       Impact factor: 5.284

5.  Gaucher disease--Norrbottnian type. I. General clinical description.

Authors:  S Dreborg; A Erikson; B Hagberg
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

6.  Electroencephalographic findings in Gaucher disease.

Authors:  R Nishimura; N Omos-Lau; C Ajmone-Marsan; J A Barranger
Journal:  Neurology       Date:  1980-02       Impact factor: 9.910

7.  [On the juvenile form of Gaucher's disease].

Authors:  C Claes; G Carpentier
Journal:  J Neurol Sci       Date:  1967 May-Jun       Impact factor: 3.181

8.  Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease.

Authors:  D P Purpura; K Suzuki
Journal:  Brain Res       Date:  1976-10-29       Impact factor: 3.252

9.  Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease.

Authors:  O Nilsson; L Svennerholm
Journal:  J Neurochem       Date:  1982-09       Impact factor: 5.372

  9 in total
  9 in total

1.  Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease.

Authors:  N G Conradi; H Kalimo; P Sourander
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 2.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 3.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

4.  Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.

Authors:  Aimee Donald; Cecilia Kämpe Björkvall; Ashok Vellodi; Timothy M Cox; Derralyn Hughes; Simon A Jones; Robert Wynn; Maciej Machaczka
Journal:  Orphanet J Rare Dis       Date:  2022-06-18       Impact factor: 4.303

5.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 6.  Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare.

Authors:  Shraga Aviner; Ben-Zion Garty; Avinoam Rachmel; Hagit N Baris; Ellen Sidransky; Avinoam Shuffer; Joseph Attias; Yisaac Yaniv; Ian J Cohen
Journal:  Blood Cells Mol Dis       Date:  2009-09-05       Impact factor: 3.039

7.  Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies.

Authors:  N G Conradi; P Sourander; O Nilsson; L Svennerholm; A Erikson
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

Review 8.  Progressive myoclonic epilepsy.

Authors:  Mary L Zupanc; Benjamin Legros
Journal:  Cerebellum       Date:  2004       Impact factor: 3.648

Review 9.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.